Phosphorus levels during infusion of parenteral nutrition with calorie-based phosphorus concentration: A case series

Fernandes, Vanessa Pacini Inaba; Pinto, Elizete Aparecida Lomazi da Costa; Boin, I.F.S.F.; Nogueira, Roberto José Negrão

doi:10.1016/j.eclnm.2009.08.001

Cited by 3 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The amount of phosphorus in mmol/kcal 21 was determined by calculating the mean quantity of phosphorus from days 1–4 divided by the mean number of calories infused. The amount of magnesium in mEq/kg and potassium in mEq/kg was determined by calculating the mean quantity of magnesium or potassium from days 1–4 divided by the patients' average weight.…”

Section: Methodsmentioning

confidence: 99%

Hypophosphatemia, Hypomagnesemia, and Hypokalemia in Pediatric Patients Before and During Exclusive Individualized Parenteral Nutrition

et al. 2016

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Hypophosphatemia, Hypomagnesemia, and Hypokalemia in Pediatric Patients Before and During Exclusive Individualized Parenteral Nutrition

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Hypophosphatemia typically occurs early after initiating therapy related to refeeding syndrome [ 116 ]. Vigilance, anticipation and early replacement of phosphate can prevent the development of severe hypophosphatemia [ 117 ].…”

Section: Etiology Of Hypophosphatemia In Cancermentioning

confidence: 99%

Hypophosphatemia in cancer patients

Adhikari

Mamlouk

Rondon‐Berrios

et al. 2021

Clinical Kidney Journal

View full text Add to dashboard Cite

Dysregulation of phosphorus homeostasis resulting in hypophosphatemia is common in cancer patients and can result in serious complications and impact outcomes. Several factors, including critical illness, nutritional status, cancer type, and therapy, influence the development of hypophosphatemia. Hypophosphatemia can develop as a result of phosphaturic mesenchymal tumors or as a paraneoplastic phenomenon. The clinical presentation for hypophosphatemia varies depending on the duration and severity of the hypophosphatemia and affects several organ systems. Among other serious effects, hypophosphatemia can impair tissue oxygenation, cause hemolysis, leukocyte and platelet dysfunction, encephalopathy, seizures, arrhythmias, cardiomyopathy, rhabdomyolysis, and coma. Multiple studies have demonstrated that hypophosphatemia is an adverse prognostic marker in inpatients with increased in-hospital stay, mortality, and postoperative complications. The phosphate level is homeostatically regulated and maintained in a narrow range by 3 main hormones: PTH, FGF-23, and 1,25 (OH)2 Vitamin D3. Together, these hormones regulate how the intestine, kidneys, and bones traffic phosphorus. Several hematological malignancies and cancer therapies are associated with proximal tubular dysfunction (Fanconi syndrome), resulting in phosphaturia. Caution should be taken with parenteral administration of phosphate salts because secondary complications can develop principally due to hypocalcemia. The general approach to hypophosphatemia should target the underlying cause. Early recognition and prevention are essential, and the approach to hypophosphatemia in the cancer patient because of the nuances and complexity should be multidisciplinary.

show abstract

Mineral Disorders in Adult Inpatients Receiving Parenteral Nutrition. Is Older Age a Contributory Factor?

Hortêncio

Golucci

Marson

et al. 2018

The Journal of nutrition, health and aging

View full text Add to dashboard Cite

show abstract

Phosphorus levels during infusion of parenteral nutrition with calorie-based phosphorus concentration: A case series

Cited by 3 publications

References 18 publications

Hypophosphatemia, Hypomagnesemia, and Hypokalemia in Pediatric Patients Before and During Exclusive Individualized Parenteral Nutrition

Hypophosphatemia, Hypomagnesemia, and Hypokalemia in Pediatric Patients Before and During Exclusive Individualized Parenteral Nutrition

Hypophosphatemia in cancer patients

Mineral Disorders in Adult Inpatients Receiving Parenteral Nutrition. Is Older Age a Contributory Factor?

Contact Info

Product

Resources

About